Skip to content
value.today

Transplant Genomics Inc.

Total raised
$17 M
4 rounds on record
Latest round
$8 M
Aug 2018
First round on record
Mar 2014
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Transplant Genomics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2018$8 MNo. 4$2 to $10 million

Transplant Genomics Inc.: Raise no. 4, Aug 2018

Investors in this round

31 investors had bought by the notice of Sep 6, 2018: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Darren Lee · Executive Officer
  • Peter Lewis · Executive Officer
  • Roy First · Executive Officer
  • Stanley Rose · Executive Officer, Director
  • Chris O'Connor · Director
  • David Kravitz · Director
  • Jay Venkatesan · Director
  • Michael Abecassis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes $3,482,961 of converted indebtedness and accrued interest.”

Signed by Stanley Rose, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 6, 2018. Read the notice at the SEC.

equity, optionsSEC
Mar 2017$3 MNo. 3$2 to $10 million

Transplant Genomics Inc.: Raise no. 3, Mar 2017

Investors in this round

27 investors had bought by the notice of Apr 5, 2017: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $6 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$31,502
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Darren Lee · Executive Officer
  • Peter Lewis · Executive Officer
  • Roy First · Executive Officer
  • Stanley Rose · Executive Officer, Director
  • Chris O'Connor · Director
  • Jay Venkatesan · Director
  • Michael Abecassis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Arcadia Securities, LLC · broker-dealer Arcadia Securities, LLC (CRD 50764) · Fort Lee, New JerseySold in NY

Remarks in the notice

  • On fees: “$16,522.46 of the Finders' Fee above is in the form of equity issued by Transplant Genomics Inc. and $1,543.54 of the Finders' Fee above is in the form of a warrant issued by Transplant Genomics Inc.”

Signed by Stanley Rose, Ceo. Source: SEC Form D, newest notice filed Apr 5, 2017. Read the notice at the SEC.

equity, optionsSEC
Nov 2014$3 MNo. 2$2 to $10 million

Transplant Genomics Inc.: Raise no. 2, Nov 2014

Investors in this round

47 investors had bought by the notice of May 28, 2015: 44 accredited, 3 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$6,296
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stanley Rose · Executive Officer, Director
  • Daniel Solomon · Director
  • Michael Abecassis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stanley Rose, President. Source: SEC Form D and 2 amendments, newest notice filed May 28, 2015. Read the notice at the SEC.

equitySEC
Mar 2014$3 MNo. 1$2 to $10 million

Transplant Genomics Inc.: Raise no. 1, Mar 2014

Investors in this round

33 investors had bought by the notice of Apr 4, 2014: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered; $0 M still to sell
Smallest investment taken
$5,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 505: the former limited-offering exemption (withdrawn in 2017)
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stanley Rose · Executive Officer, Director
  • Daniel Salomon · Director
  • Michael Abecassis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stanley Rose, President and Treasurer. Source: SEC Form D, newest notice filed Apr 4, 2014. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Transplant Genomics Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2018).

    SEC Form D · Sep 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2018

That is all the official record says: Transplant Genomics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Transplant Genomics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 47 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Transplant Genomics Inc.
NameRoleNamed in
Darren LeeExecutive officerSep 2018
Peter LewisExecutive officerSep 2018
Roy FirstExecutive officerSep 2018
Stanley RoseExecutive officerSep 2018
Chris O'ConnorDirectorSep 2018
David KravitzDirectorSep 2018
Jay VenkatesanDirectorSep 2018
Michael AbecassisDirectorSep 2018
Stanley RoseDirectorSep 2018
Daniel SolomonDirectorMay 2015
Daniel SalomonDirectorDec 2014